SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

6628 (6628) News

Follow 6628 (6628) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 6628 Asset market Sector Markets 90 days 1 Updated Oct 12, 2026, 01:11 AM UTC Open live news feed
M Transcenta Says Regulators Approve Osemitamab Global Phase III Trial Transcenta says regulators in the U.S., China and South Korea approved a global Phase III trial of osemitamab. EQUITY | Oct 12, 2026, 01:11 AM UTC